Clinical Trials
10 trialsNCT03202940 2026-05-08
A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC
Massachusetts General Hospital
Phase 1/2 Active not recruiting
NCT04409639 2026-04-24
CONCERTO
University of Utah
Phase 2 Active not recruiting
NCT03175432 2026-04-15
Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02721459 2026-03-02
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Active not recruiting
NCT03181100 2026-01-09
Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03202316 2025-12-16
Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05034627 2025-11-28
Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 1 Active not recruiting
NCT04722575 2025-03-13
NEO-TIM
Fondazione Melanoma Onlus
Phase 2 Active not recruiting
NCT03224767 2025-02-18
Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma
Alliance for Clinical Trials in Oncology
Phase 2 Active not recruiting
NCT04185831 2024-08-22
MEGALiT
Uppsala University Hospital
Phase 2 Active not recruiting